Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice

Published:2020-04-15 Issue: Volume: Page:
ISSN:2228-5881
Container-title:Advanced Pharmaceutical Bulletin
language:en
Short-container-title:Adv Pharm Bull

Author:

Daei Farshchi Adli Amir¹^ORCID,Jahanban-Esfahlan Rana¹,Seidi Khaled¹,Farajzadeh Davoud²,Behzadi Ramezan³,Zarghami Nosratollah¹⁴^ORCID

Affiliation:

1. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

2. Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran.

3. North Research Center, Pasture Institute of Iran, Tehran, Amol, Iran.

4. Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Publisher

Maad Rayan Publishing Company

Subject

General Pharmacology, Toxicology and Pharmaceutics,Pharmaceutical Science

Link

https://apb.tbzmed.ac.ir/Files/Inpress/apb-28558.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel for breast cancer therapy: A review on effective drug combination modalities and nano drug delivery platforms;Journal of Drug Delivery Science and Technology;2024-05

2. At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment;Pharmaceuticals;2023-12-01

3. Multifunctional nanostructures: Intelligent design to overcome biological barriers;Materials Today Bio;2023-06

4. Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease;Frontiers in Oncology;2022-11-30

5. Small-Molecule Drugs in Immunotherapy;Mini-Reviews in Medicinal Chemistry;2022-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3